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Objectives. This study was undertaken to assess prospectively 
the prognostic power of early ST segment elevation resolution in 
a large cohort of patients with myocardial infarction and to test 
the value of differences in ST segment resolution as a surrogate 
end point. 
Background. Previous studies revealed that the use of two cutoff 
points for three groups of ST segment resolution within 3 h after 
the start of thrombolysis is most elective in predicting outcome. 
Methods. The International Joint Efficacy Comparison of 
Thrombolytics (INJECT) trial compared mortality in 6,010 pa- 
tients randomized to receive either reteplase or streptokinase. The 
1,909 German patients form the basis of this substudy. The three 
groups of ST segment resolution were defined as complete 
(_>70%), partial (70% to 30%) and no resolution (<30% to >0%). 
Results. In 1,398 patients presenting <6 h from onset of acute 
myocardial infarction, the 35.day mortality rate for complete, 
partial and no ST segment resolution was 2.5%, 4.3% and 17.5%, 
respectively (p < 0.0001). Peak creatine kinase levels (fraction of 
normal) were 9.8, 13.4 and 14.0, respectively (p < 0.0001). When 
baseline characteristics were included, ST segment resolution was 
the most powerful independent predictor of 35-day mortality. The 
proportion of patients with complete ST segment resolution was 
larger, and that with no ST segment resolution smaller, with 
reteplase than with streptokinase (p = 0.006). 
Conclusions. No ST segment resolution, indicating failed 
thrombolysis, predicts very high early mortality, whereas com- 
plete resolution is associated with a small infarct area and low 
mortality. Partial ST segment resolution also predicts larger 
infarct areas, but early mortality is relatively low. Different 
extents of ST segment resolution may serve as a sensitive surro- 
gate end point in clinical trials. 
(JAm CoU Cardio11995;26:1657-64) 
In patients with evolving myocardial infarction, an early prog- 
nostic indicator that is easy to use in all patients is highly 
desirable. In only a few studies has resolution of electrocar- 
diographic (ECG) ST segment elevation been tested as a 
prognostic ndicator (1-3), in contrast to coronary reperfusion 
predicted by ST segment changes, which has been investigated 
by numerous investigators (4). In prior studies that predicted 
outcome for ST segment elevation resolution, one cutoff point 
was applied. As an improvement, we used two cutoff points, 
which were first applied in two smaller prospective studies 
(4,5). The validity of the model was tested in a retrospective 
analysis in 1,516 patients from the Intravenous Streptokinase 
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in Acute Myocardial Infarction (ISAM) study (6) data base, 
which provided a large, well characterized patient group for 
whom multivariate analyses could be performed to identify 
independent determinants of mortality (7). These studies 
showed that cutoff points of ST segment resolution ---70% and 
<30% are most effective for predicting infarct size, left ven- 
tricular function and early as well as long-term survival. 
In the ISAM study (6), streptokinase infusion showed only 
a nonsignificant trend in reduction of mortality. The predictive 
power of the ST segment resolution was the same regardless of
whether patients had received streptokinase or placebo infu- 
sion (7). However, there was a significant difference in the 
extent of ST segment resolution in favor of streptokinase (p < 
0.0001). 
We next conducted a substudy in conjunction with the 
International Joint Efficacy Comparison of Thrombolytics 
(INJECT) trial 1) to assess prospectively the prognostic power 
of the ECG markers in a large cohort of patients with acute 
myocardial infarction; and 2) to test prospectively the value of 
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Table 1. Reasons for Exclusion of 233 Patients From Evaluation of
Predictive Power of ST Segment Elevation Resolution* 
No. (%) of Pts 
Died before 3-h ECG 16 (0.8) 
No study drug 27 (1.4) 
No ST segment elevation 64 (3.4) 
No 3-h ECG 92 (4.8) 
Not evaluable 7 (0.4) 
Outside time window 85 (4.5) 
QRS ->0.12 ms 38 (2.0) 
BBB, no MI 16 (0.9) 
BBB, no ST ]' 8 (0.4) 
WPW syndrome 2 (0.1) 
Pacemaker 4 (0.2) 
Ideoventricular rhythm 8 (0.4) 
Total 233 (12) 
*Patients (Pts) with events of different ypes appear more than once in the 
column but only once in the total. BBB = bundle branch block; ECG = 
electrocardiogram; MI = myocardial infarction; no ST T = absence of ischemic 
ST segment elevation on prerandomization ECG; WPW = Wolff-Parkinson- 
White. 
differences in ST segment elevation resolution as a measure of 
the differential effectiveness of thrombolytic regimens. 
Methods  
The INJECT trial was a multicenter, double-blind, random- 
ized trial that compared reteplase, 10 plus 10-million unit 
double-bolus administration, with streptokinase in patients 
admitted within 12 h from the onset of acute myocardial 
infarction. Details of the rationale, design and main results of 
the study are available in the original report (8). Between 
August 1993 and September 1994, 6,010 patients were re- 
cruited from nine European countries. Patients of any age 
were eligible for randomization if they had no clear contrain- 
dications to thrombolytic therapy and had an ST segment 
elevation ->0.1 mV in at least wo limb leads or ->0.2 mV in two 
contiguous precordial ECG leads or the presence of bundle 
branch block. 
Study patients. All 1,909 patients recruited for the INJECT 
trial in Germany were considered for analysis. A 12-lead ECG 
was recorded before and 3 h after randomization, and the ST 
segment deviation was evaluated centrally, independent of and 
blinded to the other study data or results. 
For various reasons (Table 1), 233 patients (46 of whom 
were randomized >6 h from onset of acute myocardial infarc- 
tion) had to be excluded from the evaluation of the predictive 
power of ST segment resolution. Sixty-four patients (3.4%) did 
not show the required amount of ST segment elevation at 
baseline (most did not develop a definite myocardial infarc- 
tion). In 92 patients (4.8%), a 3-h ECG was not available or 
was recorded outside the 3-h time window. A broad QRS 
complex was present in 38 patients (2%). In 16 of 24 patients 
who had a bundle branch block but no ischemic ST segment 
elevations, a suspected acute myocardial infarction was not 
confirmed. (Patients with bundle branch block and ischemic ST 
segment elevation are included in the analysis.) Of the 233 
excluded patients, 34 died within 35 days (18 had received 
reteplase and 16 streptokinase); 16 of them died early, that is, 
before the 3-h ECG could be recorded. 
Because it was expected that the model of ST segment 
resolution might not be valid >6 h after symptom onset, 
evaluation of patients randomized >6 h from symptom onset 
had been prespecified inthe study protocol. Indeed, in the 278 
evaluable patients presenting >6 to 12 h, the sum of ST 
segment elevation in the prerandomization ECG was signifi- 
cantly lower than that in patients randomized earlier (anterior 
myocardial infarction 1.25 vs. 1.63 mV; inferior myocardial 
infarction 0.65 vs. 0.89 mV, both p < 0.0001). Many patients 
presenting later probably already had had a spontaneous 
decline in their initial ST segment elevation. Therefore, and to 
be consistent with previous studies (4,5,7), only the 1,398 
evaluable patients randomized <-6 h from symptom onset form 
the basis of this report. 
Electrocardiographic analysis. The sum of ST segment 
elevation was measured with lens-intensified calipers to the 
nearest 0.025 mV, 20 ms after the end of the QRS complex 
from leads I, aVL and V1 to V 6 for anterior myocardial 
infarction and leads II, III, aVF, Vs and V6 for inferior 
myocardial infarction (7). Patients with bundle branch block 
who had clear ischemic ST segment elevations were included in 
this analysis. In addition, subgroups of patients who had a 
reciprocal ST segment depression -0.1 mV were also evalu- 
ated. For the total ST segment deviation (no bundle branch 
block in this group) the sum of ST segment depression i  leads 
II, III and aVF for anterior and that in leads V 1 to V 4 for 
inferior myocardial infarction were added (9). The extent of 
epicardial injury was also quantified by counting the number of 
leads with ST segment elevation ->0.1 mV (10). 
Prognostic ST segment resolution groups. Consistent with 
the previous studies (4,7), two cutoff points of ST segment 
resolution within 3 h after start of thrombolysis were applied. 
Complete r solution was defined as resolution of the initial sum 
of ST segment elevation (or total deviation) >70%. Partial 
resolution was defined as ST segment resolution <70% to 30%. 
No resolution was defined as ST segment resolution <30% to 
->0%. For the 3-h ECG recording, a time window of 2 to 4 h 
after initiation of thrombolytic therapy was allowed; 95.5% of 
the ECGs were recorded within this time span (88.5% between 
2.5 and 3.5 h). 
Enzyme analysis. Peak creatine kinase (CK) isoenzyme 
serum activity was measured in the participating hospitals and 
is expressed as fraction of the upper normal limit for the 
different methods used. To depict the continuous relation 
between peak CK activity and ST segment resolution, moving 
averages of length 201 were used with ST segment resolution 
arranged in descending order (Fig. 1). 
Statistical analysis. For univariate analyses only nonpara- 
metric methods were applied. Comparisons between the two 
groups were performed using the Mann-Whitney U test for 
continuous variables and Fisher exact test for dichotomous 
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Figure 1. Peak creatine kinase (CK) values (fraction of the upper 
normal limit) in relation to sum (E) of ST segment elevation resolution 
continuously drawn by moving averages from 100% resolution to0~ 
resolution 3 h after the start of thrombolytic herapy. The ST segment 
resolution cutoff points of 70% and 30% are marked. 
variables (e.g., mortality). Simultaneous comparisons for more 
than two groups were performed using the Kruskal-Wallis test. 
The multivariate analysis consisted of a stepwise logistic 
regression for outcome at 35 days. In addition to the differ- 
ences between the indicator variables of the partial and no-ST 
segment resolution groups to the complete resolution group, 
12 baseline variables were offered as covariates: 1) age (taken 
as a continuous variable, unit 10 years); 2) female gender; 3) 
ex-smoker or nonsmoker', 4) history of heart failure; 5) previ- 
ous myocardial infarction; 6) diabetes mellitus; 7) history of 
angina pectoris; 8) anterior myocardial infarction; 9) acute 
heart failure; 10) Killip class >I; 11) large sum of ST segment 
elevation on the initial ECG (>1.2 mV for anterior, >0.6 mV 
for inferior myocardial infarction); and 12) treatment with 
reteplase. 
Logistic regression was performed using the procedure 
"LOGISTIC REGRESSION" of SPSS for Windows, Version 
5.0.2, choosing the forward-stepping selection method with 
ML estimates and the default criteria offered by SPSS. The 
indicator variables of the ST segment resolution contrasts were 
offered to the selection process as an entity. The odds ratios, 
confidence intervals and p values of the final model (i.e., 
adjusted for all other significant covariates) are reported. 
Results 
Study patients. The clinical characteristics of the 1,398 
study patients are presented inTable 2. The group with no ST 
segment resolution had a higher prevalence of several adverse 
baseline characteristics. Distribution of infarct location was 
virtually identical, as in the previous tudy (7), that is, in the 
group with complete ST segment resolution, ~67% of patients 
had an inferior myocardial infarction and ~33% had an 
anterior myocardial infarction; in the no-resolution group, 
these findings were reversed. 
The severity of ischemia, as assessed by the sum of ST 
segment elevation in the prerandomization ECG, and the 
extent of epicardial injury, as quantified by the number of leads 
with ST segment elevation >0.1 mV, were slightly lower in 
patients with no ST segment resolution than in those with 
partial and complete ST segment resolution. 
Table 2. Clinical Characteristics of 1,398 Patients According to ST Segment Elevation Resolution 3 h 
After Start of Thrombolytie Therapy 
ST Segment Elevation Resolution at 3 h 
Complete Partial No 
(n = 682 [49%]) (n = 418/30~]) (n = 298 [21%]) p Value 
Mean age (yr) 60.9 61.6 62.8 0.07 
~65 39% 42~ 46% 0.08 
Femalc 2492- 26q 27% NS 
Histow 
Previous MI 12C4 12¢; ~ 15% NS 
Heart failure 59~ 6c~; 9% 0.05 
Diabetes I tlg~ 16c;~ 22% < 0.0001 
Angina pectoris 25% 24e,~ 30% NS 
In-hospital event 
Anterior MI 33% 62(~c 58% < 0.0001 
BBB 2.9% 5.7q- 6.7% 0.01 
Killip class >1 I0~ 14% 23% < 0.0001 
EST j' (mY) ~ 
Anterior MI 1.72 ± 1.2 1.58 ± 0.8 1.40 _+ 0.9 < 0.01 
Inferior MI 0.89 + 0.6 0.86 ± 0.5 0.81 _+ 0.5 NS 
No. of leads with ST t ->0.1 mV* 
Anterior MI 4.7 + 1.8 4.8 ± 1.4 4.6 _+ 1.5 NS 
Inferior MI 3.4 + 1.1 3.4 ± 1.0 3.1 _+ 1.2 0.02 
*Mean value ± SD. YST T = sum of ST segment elevation on the prerandomization electrocardiogram; other 
abbreviations a in Table 1. 
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Figure 2. Thirty-five day mortality rates by percent sum (31) of ST 
segment resolution i multiple steps. The rationale for applying a
cutoff point of 70% is the development of larger infarct areas in 
patients with partial ST segment resolution associated with an increas- 
ing mortality risk over the long term for anterior myocardial nfarction 
(7). p < 0.0001 for mortality rate differences for complete, partial or no 
ST segment resolution. 
Table 4. Causes of Death According to Complete, Partial or No ST 
Segment Elevation Resolution 
No. of Pts With ST Segment Resolution at 3 h 
Complete Partial No 
(n = 682) (n = 418) (n = 298) p Value 
Cardiac deaths 
Cardiogenic shock 5 8 17 < 0.0001 
Cardiac rupture 1 1 9 < 0.0001 
Recurrent MI 1 0 5 < 0.001 
Arrhythmia 2 1 0 NS 
Other 4 7 20 < 0.0001 
Total 13 17 51 < 0.0001 
Noncardae deaths 
Stroke 2 1 1 NS 
Other 2 0 0 NS 
Total deaths 17 18 52 < 0.0001 
Abbreviations as in Table 1. 
Infarct size and mortality according to complete, partial or 
no ST segment resolution. Peak CK activity was significantly 
lower in patients with complete resolution (9.8) than in those 
with partial (13.4) or no resolution (14.0) (p < 0.0001). Peak 
CK activity gradually increased from 7.1 (fraction of the upper 
normal imit) at 100% ST segment resolution to 13.3 at 70% 
(range for complete resolution) and leveled off thereafter at 
~13.4 until 30% (partial) and -14 from <30% to ->0% ST 
segment resolution (range for no ST segment resolution) (see 
Fig. 1). 
The 35-day mortality rates by percentage of ST segment 
resolution in multiple steps are shown in Figure 2. Patients 
with complete ST segment resolution have a very low mortality 
risk of only 2.5%; they comprise nearly one-half of all study 
patients (34% of anterior and 62% of inferior myocardial 
infarction patients). In contrast, no ST segment resolution, as 
observed in 21% of patients (26% anterior, 17% inferior 
infarction), was associated with an exceptionally unfavorable 
outcome (17.5% mortality rate). In Table 3, the mortality rates 
of the subgroups with anterior or inferior myocardial infarction 
(bundle branch block excluded) and for patients with bundle 
branch block are presented. Mortality is similarly low, with 
complete ST segment resolution i  both infarct locations. High 
mortality with no ST segment resolution is more common in 
patients with anterior myocardial infarction, especially in the 
subset of those who had reciprocal ST segment depression on 
their initial ECG. Mortality is exceptionally high in patients 
with bundle branch block and no resolution of the initial 
ischemic ST segment elevation. 
Causes of death are given in Table 4. There was no difference 
in the incidence of arrhythmia deaths between the three resolu- 
tion groups; however, all other causes of cardiac death were more 
often associated with no ST segment resolution. 
Prognostic impact of extent of ST segment resolution in 
risk subsets. Various cardiac event rates subdivided by the 
three resolution groups are presented in Table 5. Malignant 
tachyarrhythmias, cardiogenic shock and heart failure were 
observed more often with no ST segment resolution. 
The 35-day mortality rate by clinical variables, identified or 
known (7) to be independent predictors of survival, are shown 
in Table 6. For each risk subset, mortality was low (at least 
relatively so) with complete ST segment resolution but ex- 
tremely high with no ST segment resolution. Of special note is 
the mortality rate of 62% in patients with recurrent myocardial 
infarction, who had had no ST segment resolution, and the 
relatively low mortality rate of 33% in patients with cardio- 
genie shock, whose initial ST segment elevation completely 
resolved 3 h after the start of thrombolysis. 
Table 3. Thirty-Five Day Mortality Rate According to Complete, Partial or No ST Segment 
Resolution i Subgroups of1,398 Patients Presenting -<6 h From Symptom Onset 
Mortality Rate (%) by ST Segment Resolution at 3 h 
Complete Partial No p Value 
Anterior M1 1.9 (4/212) 2.9 (7/242) 17.2 (27/157) < 0.0001 
ST segment depression 1.6 (2/122) 3.4 (4/117) 24.2 (16/66) < 0.0001 
inferior MI 2.7 (12/450) 5.9 (9/152) 14.0 (17/121) < 0.0001 
ST segment depression 2.9 (9/314) 5.1 (5/98) 14.5 (11/76) < 0.0001 
BBB 5.0 (1/20) 8.3 (2/24) 40.0 (8/20) < 0.005 
Numbers in parentheses are number of patients. ST segment depression = resolution of total ST segment deviation 
in the subsets of patients who had reciprocal ST segment depression on their initial electrocardiogram; other 
abbreviations a in Table 1. 
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Table 5. Clinical Event Rate* According to Complete, Partial or No ST Segment Elevation Resolution 
Event Rate (%) by ST Segment Elevation Resolution at3 h 
Total No. of Pts 
With Events Complete Partial No p Value 
Recurrent MI 90 6.2 (42) 5.3 (22) 8.7 (26) NS 
AP/ischemia 171 13 (87) 10 (41) 14 (43) NS 
PTCA/CABG 329 27 (186) 20 (83) 20 (60) < 0.01 
VF/VT 222 13 (89) 15 (63) 24 (70) < 0.0005 
Killip class >I 192 10 (67) 14 (57) 23 (68) < 0.0001 
Heart failure 265 13 (89) 20 (81) 32 (95) < 0.0001 
Cardiogenic shock 84 2.6 (18) 3.8 (16) 17 (50) < 0.0001 
*Present after enrollment. Numbers inparentheses arenumber of patients. AP = angina pectoris; CABG = coronary 
artery, bypass graft surgery; PTCA = percutaneous transluminal coronary angioplasty; VF = ventrieular fibrillation; VT 
= sustained ventricular tachycardia; other abbreviations as in Table 1. 
Multivariate logistic regression analysis revealed five covari- 
ates that were independent predictors of 35-day mortality 
(Table 7). The entity of the ST segment resolution groups is 
the most powerful, with an odds ratio of 6.9 for no versus 
complete ST segment resolution. 
Comparison of reteplase and streptokinase. Of all 1,585 
patients randomized -<6 h from symptom onset, 111 (7%) died 
by day 35; 49 (6.3%) of 782 had received reteplase, and 62 
(7.7%) of 803 had received streptokinase. The mortality rate in 
the patients evaluated was 87 (6.2%) of 1,398: reteplase in 36 
(5.2%) of 692 and streptokinase 51 (7.2%) of 706. None of the 
mortality differences was statistically significant (p = 0.26 for 
all patients, and p = 0.12 for all patients evaluated). However, 
there was a significant difference in the extent of ST segment 
elevation resolution (p = 0.006). More patients had complete, 
and less had no, ST segment resolution in the reteplase group 
(Table 8). These differences remained significant even when 
patients who were randomized >6 h from symptom onset were 
included into the analysis (p = 0.02). 
Discuss ion  
Ideally, an early prognostic indicator in patients with acute 
myocardial infarction should be simple, quick, noninvasive and 
easy to use in all patients. An assessment by ECG criteria 
would fulfill all of these claims. Early ST segment elevation 
resolution has been tested in a few studies by applying one 
cutoff point of ST segment resolution. Saran et al. (1) used 
a cutoff point <30% ST segment resolution at 3 h in 45 
patients. Barbash et al. (2) used 50% reduction after 1 h in 
286 patients, and Mauri et al. (3) used 50% reduction 4 h 
after the start of thrombolysis in a Gruppo Italiano per lo 
Studio della Sopravvivenza nell'Infarto Miocardico (GISSI 
2)-derived analysis of 7,426 patients. Consistently, a lesser 
degree of ST segment resolution was associated with a 
significantly worse outcome. However, these studies had the 
limitation that the groups with greater ST segment resolu- 
tion included too many patients with still severely depressed 
left ventricular function, and, vice versa, the groups with 
Table 6. Thirty-Five Day Mortality Rate by Risk Group According to Complete, Partial or No ST 
Segment Elevation Resolution 
Mortality Rate (%) by ST Segment Elevation Resolution 
at3 h 
No. of Pts. Complete Partial No p Value 
<65 yr old 21/821 0 2 10 < 0.0001 
->65 yr old 66/577 6 7 26 < 0.0001 
Male 49/1,045 2 3 14 < 0.0001 
Female 38/353 5 7 28 < 0.0001 
Clinical event* 
Recurrent M1 25/90 12 18 62 < 0.0001 
Killip class >I 30/192 4 7 34 < 0.0001 
Heart failure 39,/265 3 l I 28 < 0.0001 
Cardiogenic shock 56/84 33 63 80 < 0.005 
History 
Previous M1 18/171 3 17 18 < 0.01 
Diabetes 26/203 4 7 27 < 0.0001 
Angina pectoris 38/362 5 10 22 < 0.0001 
Heart failure 20/85 14 17 41 < 0.05 
*Present after enrollment. Abbreviations a  in Table 1. 
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Table 7. Multivariate Analysis for Prediction of 35-Day Mortality 
Based on ST Segment Resolution Groups and 12 Other Variables in 
1,398 Patients Presenting -<6 h After Symptom Onset 
Selected at OR 
Variable Step (95% CI) p Value 
ST segment resolution 1 < 0.0001 
Partial vs. complete 1.6 (0.8-3.3) NS 
No vs. complete 6.9 (3.8-12.5) < 0.0001 
Age (10-yr steps) 2 2.2 (1.7-2.8) < 0.0001 
History of heart failure 3 2.5 (1.3-4.7) 0.006 
Acute heart failure 4 2.1 (1.3-3.5) 0.004 
History of angina 5 1.7 (1.0-2.7) 0.04 
CI = confidence interval; OR = odds ratio. 
lesser ST segment resolution included patients with a rela- 
tively favorable outcome. 
We proposed to solve this problem by applying two cutoff 
points, which created three groups of ST segment resolution 
with complete (->70%), partial (<70% to ->30%) or no 
(<30%) ST segment resolution (4,5,7). The present substudy 
of the INJECT trial, using a large and well defined patient 
cohort, confirms the strong prognostic power of the simple 
ECG marker available 3 h after the start of thrombolytic 
therapy. To be consistent with previous studies (4,7), 278 
patients presenting >6 h after symptom onset were excluded 
from the present analysis, although the results remain virtually 
the same when all randomized patients are analyzed. Because 
patients presenting later had already had a spontaneous de- 
cline in their initial ST segment elevation, the predictive power 
of (further) ST segment reduction may be limited. However, 
complete ST segment resolution in these patients was still 
associated with low mortality (none of 71 patients died), 
although there was no mortality difference in patients with 
partial (10.5%) or no ST segment resolution (9.1%). There- 
fore, whether the ECG marker is also useful in patients 
presenting later is unclear. 
Prognostic value of either complete or no ST segment 
resolution. Complete ST segment resolution in -50% of all 
patients predicts an excellent survival. None of 419 patients 
<65 years old died by 35 days. In patients with potentially 
larger infarctions, as evidenced by anterior infarct location, 
bundle branch block or additional reciprocal ST segment 
depression on the initial ECG, mortality differences between 
complete or no ST segment resolution are more distinct. In all 
patient groups known to be generally at higher risk of dying, 
complete ST segment resolution still signifies a favorable 
outcome. A lower incidence of adverse cardiac events (Tables 
4 and 5) and an improved survival (Table 6) in patients 
exhibiting ->70% ST segment resolution within 3 b after 
initiation of thrombolytic therapy are consistent with improved 
early reperfusion and limitation of infarct size. In contrast, lack 
of ST segment resolution, as observed in 17% of reteplase- 
treated and 25% of streptokinase-treated patients, indicating 
persistent ischemia and probably failed thrombolysis, is asso- 
ciated with an exceptionally high mortality risk. 
At the cutoff point of <30% ST segment resolution, there is 
an abrupt, massive increase in early mortality (Fig. 2) similar to 
that observed in the ISAM study-derived analysis (7). This 
finding is at variance to the GISSI-2-derived ata, which show 
a more gradual increase in mortality rate, from 3.1% with 
100% ST segment resolution to 11.1% with < 10% ST segment 
resolution (3). However, 41% of all GISSI study patients were 
excluded from the evaluation. The 30-day mortality rate was 
4.8% in the evaluated group compared with 9.4% in the entire 
study population. Thus, the secondary analysis is limited to a 
relatively low risk population. Furthermore, to demonstrate a 
direct relation between mortality and the percent reduction in 
ST segment elevation, apparently data for 6-too mortality are 
provided (stated as in-hospital mortality in the paper). Because 
mortality "catches up" over the long term in patients with 
partial ST segment resolution (7), an early 30% ST segment 
resolution gap may already have somewhat smoothed off at 
6 mo. 
Lack of ST segment resolution in the present study is 
associated with a 35-day mortality rate of 17.5%, whereas with 
->30% ST segment resolution the 35-day mortality rate was 
3.2% (2.5% with complete, 4.3% with partial ST segment 
resolution). As in the ISAM study-derived analysis (7), lack of 
ST segment resolution within 3 h after the start of thrombolysis 
was the most powerful independent predictor of early mortal- 
ity. This prognostic power may even be greater than that of the 
patency status of the infarct-related artery as assessed anglo- 
graphically at 90 min after the start of thrombolysis. A 
meta-analysis of the major published trials reporting the 
Table 8. Percent of Patients With Complete, Partial or No ST Segment Elevation Resolution 
Allocated to Receive Reteplase or Streptokinase 
All Pts Anterior MI lnferior MI 
RP SK RP SK RP SK 
In - 692) (n = 706) (n - 318) (n = 337) (n = 374) (n = 369) 
ST segment resolution 
(no. of pts) 
Complete 51 46 36 33 65 59 
Partial 31 29 43 37 22 21 
No 17 25 22 31 14 20 
p value 0.006 0.08 0.04 
RP = reteplase: SK = streptokinase: other abbreviations as in Table l. 
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relation between mortality and patency status of the infarct- 
related artery in 3,960 patients (11) revealed amortality rate of 
3.8% for complete vessel patency, whereas with an occluded 
artery or sluggish flow only (Thrombolysis in Myocardial 
Infarction [TIMI] grade 2 flow), the mortality rate was 8.9% 
and 6.7%, respectively. It appears that different extents of ST 
segment resolution within 3 h after the start of thrombolysis 
contain more comprehensive, prognostically important infor- 
mation than does the patency status of the infarct-related 
artery alone (4). Persistent ischemia t 3 h identifies a high risk 
group more clearly than a "snapshot" view of coronary patency 
at 90 min, which does not allow differentiation between 
patients with improving, stable or deteriorating infarct vessel 
patency (11). 
Partial ST segment resolution. Although <30% ST seg- 
ment resolution predicts high early mortality, <70% ST seg- 
ment resolution predicts larger infarct areas. Peak CK activity 
as used in the present study is not the best index of infarct size 
because this measure is known to be further elevated by 
effective thrombolysis (6). However, when more precise mea- 
sures, such as infarct size calculated from CK-MB release or 
development ofQ waves, and left ventricular function assessed 
by cineangiography 1 mo after myocardial infarction were 
used, 70% ST segment resolution was also an excellent cutoff 
point for predicting infarct size (7). 
According to studies (1,4,12-14) comparing angiographic 
vessel patency and ST segment changes, even only partial ST 
segment resolution (between ->30% and <70%) indicates 
reperfusion i  most patients. However, in these studies TIMI 
grade 2 and 3 flow has been considered patent. It is now well 
established that TIMI grade 2 flow should be considered 
occluded and designated as reperfusion failure rather than 
success (11). Krucoff et al. (15) evaluated patency status by 
means of a newer technique of ST segment recovery analysis 
during continuous 12-lead ECG. They found that ST segment 
changes probably comparable to our partial ST segment reso- 
lution may occur with TIMI grade 2 flow as well as with 
collateralized occlusion. Other mechanisms involved in the 
development of larger infarct areas identifiable by partial ST 
segment resolution may include abrupt reopening of an ini- 
tially persistent complete occlusion of a major coronary branch 
(16,17) and relatively late reperfusion (4). Whatever the 
mechanisms are, the relatively low early mortality indicates 
that patients with partial ST segment resolution may still have 
benefited from thrombolysis. Even small changes in left ven- 
tricular function may be of particular importance in patients 
with poor left ventricles to begin with. However, some subsets, 
like those with cardiogenic shock or a history of previous 
myocardial infarction, may require complete ST segment res- 
olution to predict improved survival (Table 6). 
Comparison of reteplase and streptokinase. Reteplase isa 
recombinant mutant of tissue-type plasminogen activator (t- 
PA) with a longer half-life than alteplase (8). It provides 
significantly higher 90-min patency rates than the traditional 
3-h infusion of alteplase (18-20). Early TIMI grade 3 flow is 
comparable or even superior (21) to that obtained by the 
accelerated t-PA regimen introduced by Neuhaus et al. (22). 
More rapid and complete restoration of coronary flow through 
the infarct-related artery is believed to be the principal mech- 
anism by which accelerated t-PA improves urvival (23). To- 
day, the prognostic significance of early TIMI grade 3 flow is 
generally accepted. However, to achieve a statistically signifi- 
cant 14% relative reduction in mortality with accelerated t-PA, 
compared with streptokinase, >40,000 patients were random- 
ized in the Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Coronary Arteries 
(GUSTO) trial (23). By analogy, to prove directly a mortality 
benefit for reteplase compared with streptokinase, a trial on 
the GUSTO scale would be needed (8). Because it is obviously 
impossible to conduct a megatrial to prove the benefit of each 
new thrombolytic agent, each new treatment regimen or the 
advantage of antithrombotic or other adjunctive treatments, 
there is clearly the need for a more practical means of 
evaluation that enables us to compare innovative thrombolytic 
regimens in much smaller trials (8,24). 
There is a very close correlation between cardiac mortality 
and extent of ST segment elevation resolution in patients with 
evolving myocardial infarction. Therefore, a larger extent of 
ST segment resolution may serve as a surrogate for improved 
survival. In trials not primarily designed to assess mortality 
differences, different extents of ST segment resolution may 
provide a sensitive measure of differential clinical benefits. The 
much larger number of ST segment resolution end points can 
provide statistically significant results with much less resources 
than would be needed for differences inmortality. As expected, 
the statistical power for differences in ST segment resolution 
between streptokinase and placebo was stronger (7) than that 
between reteptase and streptokinase. However, a clear benefit 
for reteplase still exists. Taking into account he satisfactory 
safety profile observed for reteplase (8), higher early vessel 
patency and better ST segment resolution may also serve a 
surrogate nd points, suggesting that reteplase is superior to 
streptokinase. 
Clinical implications. Patients with complete ST segment 
resolution may be scheduled for early discharge without rou- 
tine angiography. Only patients with suspected extensive cor- 
onary artery disease and those with recurrent ischemia or 
stress test results indicative of ischemia should be considered 
for angiography and revascularization maneuvers. In patients 
with lack of ST segment resolution, identifying those patients 
who have a poor prognosis without reperfusion and patients in 
whom reperfusion might be expected to provide substantial 
benefit, early angiography and revascularization may be indi- 
cated (25). Patients with partial ST segment resolution, in 
whom the risk prediction is less conclusive, may require a more 
extensive diagnostic assessment of their cardiac status and 
therapeutical pproach. In the ISAM study-derived analysis 
(7), over the long term, patients with anterior myocardial 
infarction and partial ST segment resolution carried an in- 
creasing mortality risk. 
Study limitations. There are some factual or putative 
limitations of the present study. 
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1. Thirteen percent of patients randomized within -<6 h 
from symptom onset were excluded from the evaluation of the 
prognostic power of ST segment resolution within 3 h after the 
start of thrombolysis. Assuming the worst case scenario, that is, 
that all patients who survived the first 3 h would have had 
complete ST segment elevation resolution, the mortality rate 
at 35 days would account for 3.3% instead of the 2.5% 
evaluated. Therefore, the exclusion of patients virtually did not 
affect he results. 
2. The time window for the 3-h ECG was 2 to 4 h, which 
may appear ather large. We also performed all calculations 
applying atime window of 2.5 to 3.5 h. The results are virtually 
the same, that is, inclusion of the 93 patients (four died at day 
35) who were in the wider time window did not affect the 
results. These findings, indicating that a strict time of 3 h after 
the start of thrombolysis not mandatory for recording the 
"3-h ECG," are noteworthy and an advantage rather than a 
disadvantage of the model. 
3. Exact measurement of he sum of ST segment elevations 
is cumbersome and would affect he simplicity of the model. 
However, in most cases exact measurements are not needed 
because they can easily be identified by visual comparison of 
the two ECG tracings as having either almost complete or 
almost no ST segment elevation resolution. In addition, ST 
segment resolution measured only in the one lead with initially 
high ST segment elevation closely correlates with the sum of 
ST segment resolution (r = 0.93). 
Conclusions. The amount of ST segment resolution within 
3 h after the start of thrombolytic therapy conveys very useful 
information about he outcome in patients with acute myocar- 
dial infarction of -<6 h duration and may also serve as a 
sensitive surrogate nd point in clinical trials. The predictive 
power of this simple, noninvasive, arly marker of prognosis, 
which is easy to use in all patients who survive 3 h after 
admission, is extraordinarily strong and helpful for timely 
triage of patients to appropriate therapeutic interventions. 
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